Adult stem cell

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Retrieved on: 
Tuesday, July 27, 2021
Research, FDA, Clinical trials, Philanthropy, Stem cells, Biotechnology, General Health, Health, Foundation, Science, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Mesenchymal stem cell, Adult stem cell, Stem-cell therapy, Shimon Slavin

Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).

Key Points: 
  • Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).
  • A single infusion in the treatment group consists of 200 million stem cells, or approximately 1.2 billion stem cells per patient over the course of study.
  • HBSCRF remains the only organization globally to administer pure, fresh mesenchymal stem cells, an adult stem cell harvested from fat, in such high quantities over repeat treatments.
  • Clinical trial authorizations encompass COVID-19 prevention and treatment , traumatic brain injury , Parkinsons disease , and multiple sclerosis.

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Mesenchymal stem cell, Adult stem cell, Induced stem cells, Shimon Slavin

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS).

BioRestorative Therapies to Present at the Emerging Growth Conference on June 9, 2021

Retrieved on: 
Monday, June 7, 2021
Biology, Branches of biology, Life sciences, Biotechnology, Stem cells, Induced stem cells, Adult stem cell

BioRestorative Therapies invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the online Emerging Growth Conference.

Key Points: 
  • BioRestorative Therapies invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the online Emerging Growth Conference.
  • MELVILLE, N.Y., June 07, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company or BioRestorative) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, is pleased to announce that it is has been invited to present at the online Emerging Growth Conference on June 9, 2021.
  • The Emerging Growth Conference will be held on June 9, 2021.
  • BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as a Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cloning, Cell biology, Adult stem cell, Immunotherapy

Depletion of T regulatory cells was capable of reducing some of the symptoms of schizophrenia in mice.

Key Points: 
  • Depletion of T regulatory cells was capable of reducing some of the symptoms of schizophrenia in mice.
  • "We are hoping to use the immunomodulatory properties of adult stem cells to alter several neurological abnormalities that we and others have identified in schizophrenia.
  • To our knowledge, we are the only group utilizing immunology and stem cells to approach this horrific condition."
  • "This is exciting data and a prime example of the great synergy between our spin-off, Campbell Neurosciences and Therapeutic Solutions," said Timothy Dixon, President and CEO of Therapeutic Solutions International and co-inventor.

Asymmetrex Introduces Therapeutic Stem Cell Dosage Technologies to Biotherapeutics Bioprocessing Companies

Retrieved on: 
Thursday, May 20, 2021
Branches of biology, Biology, Stem cells, Life sciences, Stem-cell therapy, Hematopoietic stem cell transplantation, Stem-cell line, Adult stem cell

The simple answer he gave was that, "For the past 60+ years of stem cell medicine, there has been no way to determine the stem cell dosage of stem cell treatments.

Key Points: 
  • The simple answer he gave was that, "For the past 60+ years of stem cell medicine, there has been no way to determine the stem cell dosage of stem cell treatments.
  • Now that Asymmetrex\'s kinetics stem cell (KSC) counting technology makes it possible to determine the specific dosage of all therapeutic tissue stem cells, it just makes good science, good medicine, and good sense to start using stem cell-specific dosage.
  • "\nIn addition to addressing the long unmet need for knowing the stem cell dosage of tissue stem cell treatments and gene therapy treatments, which target tissue stem cells, Sherley discussed how technologies that quantify tissue stem cells specifically also had high impact applications for pharmaceutical and biopharmaceutical drug evaluations.
  • Asymmetrex markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Asymmetrex Will Discuss the Impact of Its Technology for Dosing Therapeutic Stem Cells

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Induced stem cells, Transplantation medicine, Stem-cell therapy, Hematopoietic stem cell transplantation, Cell therapy, Adult stem cell

Asymmetrex\'s first-in-kind kinetic stem cell (KSC) counting technology provides an effective solution to the decades old dilemma of there being no means to determine the stem cell dosage of stem cell treatments.\nSherley will be presenting the company\'s most recent improvements in its KSC counting technology.

Key Points: 
  • Asymmetrex\'s first-in-kind kinetic stem cell (KSC) counting technology provides an effective solution to the decades old dilemma of there being no means to determine the stem cell dosage of stem cell treatments.\nSherley will be presenting the company\'s most recent improvements in its KSC counting technology.
  • KSC counting can distinguish tissue stem cells, which are curative, from committed progenitor cells, which are not.
  • Finally knowing the stem cell dosage of stem cell treatments must necessarily be better for patients.
  • Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Biology, Stem cells, Life sciences, Mesenchymal stem cell, Stem-cell therapy, Stem-cell line, Cell therapy, Induced pluripotent stem cell, Adult stem cell, Cell potency

b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.

Key Points: 
  • b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.
  • However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.\nThe adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the Stem Cell Therapy Market in 2020.\nBased on the cell source from which stem cells are obtained, the global market is segmented into four sources.
  • These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines).
  • In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries.

Stem Cell Therapy Market worth $401 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Biology, Stem cells, Life sciences, Mesenchymal stem cell, Stem-cell therapy, Stem-cell line, Cell therapy, Induced pluripotent stem cell, Adult stem cell, Cell potency

b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.

Key Points: 
  • b'The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants.
  • However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.\nThe adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the Stem Cell Therapy Market in 2020.\nBased on the cell source from which stem cells are obtained, the global market is segmented into four sources.
  • These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines).
  • In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries.

BioRestorative Therapies Announces Notices of Allowance for Three Patent Applications for its Off-the-Shelf ThermoStem® Program

Retrieved on: 
Monday, March 22, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Connective tissue, Cell biology, Developmental biology, Adult stem cell, Adipose tissue, Brown adipose tissue, Stem cell transplantation for articular cartilage repair

The notices of allowance were for a total of three patent applications and covered the United States, Israel, France, Germany, Italy, Spain, and the United Kingdom.

Key Points: 
  • The notices of allowance were for a total of three patent applications and covered the United States, Israel, France, Germany, Italy, Spain, and the United Kingdom.
  • These patent allowances will allow for the protection of a specific isolated human brown adipose tissue-derived stem cell capable of differentiating into multiple cell types and their applications.
  • Our ThermoStem Program is a platform technology that we expect will create a valuable therapeutic pipeline for BioRestorative.
  • BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.

Stem Cells Market Size Worth $18.4 Billion By 2028 | CAGR: 8.8%: Grand View Research, Inc.

Retrieved on: 
Tuesday, March 9, 2021
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Developmental biology, Cloning, Mesenchymal stem cell, Trophoblast, Stem-cell therapy, Adult stem cell

SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc.
  • The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells.
  • The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response.
  • Grand View Research has segmented the global stem cells market on the basis of product, application, technology, therapy, and region:
    Stem Cells Product Outlook (Revenue, USD Million, 2017 - 2028)